Pathological complete response to NACT varied as a function of IHS – neither of the patients with HER2 enriched tumours, 3/9 (33%) patients with triple negative tumours and 3/24 (12.5%) patients with luminal B tumours had a complete pathological response. This evidence concerns the gene ERBB2 and neoplasm.